Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2025—Five years ago, many of us were grappling with the earliest cases of a novel coronavirus in the United States. During the COVID-19 pandemic that ensued, we pathologists became more visible in a variety of ways, both to our clinical colleagues and to the general public.
February 2025—Pulmonary complications cause significant morbidity and mortality in post-hematopoietic stem cell transplantation. The histopathology of pulmonary diseases in the context of post-hematopoietic stem cell transplantation (post-HSCT) is poorly characterized, especially in the pediatric population. The authors sought to characterize the pathologic spectrum of pulmonary disease post-HSCT in a pediatric cohort. Fifty-six specimens, including 53 biopsy specimens, corresponding to 53 patients were identified. Biopsy slides were reviewed and assigned to diagnostic categories (infectious, graft-versus-host disease, vasculopathy, indeterminate, and others) by consensus among three pediatric pulmonary pathologists, taking into consideration pathologic, clinical, radiologic, and laboratory findings.
February 2025—Low titer group O whole blood is commonly used for severe bleeding in trauma patients. It may also benefit pediatric patients undergoing cardiopulmonary bypass who are at risk for massive bleeding and coagulopathies. Circuit anticoagulation, hypothermia, hemodilution, coagulation factor, platelet loss and dysfunction, an underdeveloped hemostasis system in patients younger than two years old, and other factors lead to a higher risk of bleeding. Compared with component therapy, whole blood contains higher concentrations of RBCs, platelets, and coagulation factors, as well as cold platelets with enhanced hemostatic function. Due to the logistical challenges of donor centers providing ABO-specific whole blood for cardiopulmonary bypass (CPB), the use of longer storage-age low titer group O whole blood (LTOWB) may be an option for younger pediatric patients with severe bleeding on CPB.
February 2025—Excision repair cross-complementation group two (ERCC2) is a tumor-suppressor gene involved in DNA repair. Compound heterozygous mutations in ERCC2 are linked to rare recessive disorders, such as xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy, all of which are characterized by ultraviolet light sensitivity. Somatic ERCC2 mutations in cancers, particularly bladder cancers, have emerged as significant prognostic markers. The mutations predict platinum sensitivity and correlate with favorable outcomes in patients with bladder cancer, but they have not been identified as independent prognostic indicators due to a lack of data, resulting from limited cohort sizes. The authors conducted a study in which they investigated the impact of ERCC2 hotspot mutations on genomewide mutagenesis and their implications for cancer prognosis and therapeutic stratification.
February 2025
Q. Is a pathology review on all cerebrospinal fluid (CSF) specimen differential slides necessary? Should the review be based on the number of white blood cells counted or the abnormality of the differential, or both? Read answer.
Q. At what level or time is aPTT considered incorrect? Is an aPTT of less than 22.0 seconds an acceptable result? Read answer.
February 2025—When NYU Langone Health began focusing on digital pathology last year, it also began focusing on people—those it would need to keep such a program humming along. “When we were setting up this operation, it was pretty obvious to me that I wanted to have a dedicated team of people that are going to focus just on digital pathology,” says Rui Soares, anatomic pathology operations director at NYU Langone, a multisite system with approximately 80 pathologists at four hospitals. It would be “unfair,” he adds, to expect laboratory assistants to learn and perform such specialized tasks while performing other duties.
February 2025—Roche’s whole slide imaging system, Roche Digital Pathology Dx, received an additional 510(k) clearance from the Food and Drug Administration. This latest clearance modifies the one Roche received in June 2024 for Roche Digital Pathology Dx, which includes the Ventana DP 200 slide scanner.
January 2025—A clinical laboratory team at Ohio State University Wexner Medical Center took on a point-of-care testing problem common to other hospitals: documentation of critical result notification. At OSU, the documentation rate for point-of-care glucose critical result notification wasn’t high enough, and the team set out to raise it. It’s not sufficient to notify the physician or other provider. “You then have to prove you’re doing this, with documentation that the notification did in fact exist,” said Heather Stieglitz, PhD, D(ABCC), OSU co-director of clinical chemistry and toxicology, in an ADLM point-of-care testing session last summer.
January 2025—If a much younger version of me could time-travel from the 1980s to today, that young man with his full head of hair would be hard-pressed to recognize modern pathology practice. Forty years ago, I was the junior member in a private practice group in New Orleans. There were five of us in the group, covering three hospitals, with four of us based at the largest facility and one pathologist at the second hospital. And one of us would occasionally travel to the third facility, a 60-bed small-town hospital about 80 miles away, to do prescheduled frozen sections. (Can you guess who got that responsibility? I became very familiar with long-distance driving at 6:00 AM.)
January 2025—The Food and Drug Administration published a letter in December 2021 detailing the risk of false-positive rapid plasma reagin test results when using Bio-Rad Laboratories’ BioPlex 2200 Syphilis Total and RPR kit to test people who had received the COVID-19 vaccine. It did not appear that Treponema pallidum particle agglutination assays were impacted by this issue. Several U.S. and Canadian blood collection organizations noted an unconfirmed increase in syphilis screening test reactivity rates, including unconfirmed repeat reactive rates, during the COVID-19 pandemic. In an investigation of this issue at the authors’ institution, which involved assessing syphilis testing records, the authors saw no change in nontreponemal testing results but did observe an incidental increase in test reactivity with the Beckman Coulter PK TP Microhemagglutination assay for detecting T. pallidum antibodies in 2020 and 2021. The authors conducted a study to explore the false-positive syphilis results using a different institutional assay and calculate the reactivity rate of syphilis screening with negative confirmatory testing from 2011 to 2023.
